Madrigal Pharma (MDGL.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec19

Piper Sandler Raises Madrigal Pharmaceuticals' Target Price to $900

18:58

Dec11

B. Riley Securities Raises Madrigal Pharmaceuticals Target Price to $670

20:06

Dec4

Madrigal Pharmaceuticals insiders sold $1,380,816 worth of shares

22:48

Madrigal Pharmaceuticals CEO Plans to Sell 2,400 Shares of Restricted Stock

22:16

Galmed Pharmaceuticals Grants New Use Patent for ARAMCHOL in Combination with Madrigal Pharmaceuticals' REZDIFFRA

13:35

Dec3

Madrigal Pharmaceuticals CFO Reports on Stock Disposal

23:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 287.27 M, Net Income -114.19 M, EPS -5.079

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 212.8 M, Net Income -42.28 M, EPS -1.9039

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 137.25 M, Net Income -73.24 M, EPS -3.3152

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change